Abstract

High throughput Screening (HTS) is a key element of the early drug discovery process and essential for the identification of molecules with suitable target-specific properties to develop a promising drug. In our fully automated laboratory, we can offer perfectly miniaturized, cost-effective assays for HTS campaigns. Our equipment enables both microplate-intensive screening of complex compound libraries on a large scale and focused screening of smaller sub-libraries consisting of well-selected, promising structural families.

High Content Imaging (HCI) is very versatile to address your biological question at any stage of early drug discovery. Our expertise enables you to perform large scale phenotypic screening campaigns in optimal runtimes well known from standard primary approaches. We support you during labor-intensive SAR studies with a well-developed set of target-based mechanistic HCI assays. To answer your questions, we can use 2D cell models as well as highly complex 3D tumor models. Analysis of the spatial cell-dependent substance effect, at fixed predefined time points or in a dynamic system over time, is made available by using multiparametric live-cell observations in all microtiter plate formats.

In this 45-minute presentation, Dr Florian Fuchs, Laboratory Head Screening at NUVISAN-ICB and Dr Stefan Prechtl, Principal Scientific Advisor at CELLIMA, will reflect on the impact of High Content Imaging and its use during preclinical stage. Their presentation will cover:

• History of High Content imaging
• The role of High Content Imaging in the value chain
• High Content Imaging applied on more physiological relevant models
• Future impact of High Content Imaging
• Live Q&A session